Stock Analiz

NU Skin Enterprises, Inc. NUS

Other Pharmaceuticals · IPO 1996 · data as of November 13, 2026

$4.03Market cap $196M
Open the interactive analysis →

NU Skin Enterprises, Inc. (NUS) is a healthcare company listed in the US with a market value of about $196M. In the twelve months to September 30, 2026 it had revenue of $1.3B and net income of -$234M, a net margin of -17.7%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is shareholder returns (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -10% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 29% below the current price.

About NU Skin Enterprises

NU Skin Enterprises is listed in the US and classified in other pharmaceuticals, IPO year 1996. Revenue went from $2.6B in 2014 to $1.5B in 2025, a decline of about 4.9% a year. It was profitable in 9 of the last 10 years in our data. It spends 1% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns3/5

Checks passed

  • Profit margin improving
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Pays a dividend
  • Dividend 3 years in a row
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.1
P/B0.4
EV/EBITDA12.7
PEG—
Dividend yield5.92%
FCF yield-13.4%
Shareholder yield16.1%
Intrinsic value vs. price−29%

Growth and quality

Revenue growth (1 yr)-14.3%
Revenue growth (5 yrs, per year)-10.5%
EPS growth (5 yrs, per year)-2.6%
FCF growth (3 yrs, per year)-2.1%
Net margin (5-yr avg.)2.6%
ROIC (5-yr avg.)2.6%
Profitable years (of last 10)9
Years paying a dividend10

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1.3B$1.5B$1.7B$2.0B$2.2B$2.7B$2.6B$2.4B$2.7B$2.3B$2.2B
Net income-$234M$160M-$147M$9M$105M$147M$191M$174M$122M$129M$143M
Free cash flow-$26M$46M$70M$60M$49M$73M$315M$112M$132M$242M$225M
EPS (diluted)$-4.85$3.18$-2.95$0.17$2.07$2.86$3.63$3.10$2.16$2.36$2.55
Net margin-17.7%10.8%-8.5%0.4%4.7%5.5%7.4%7.2%4.5%5.7%6.5%
ROIC—4.9%-11.3%2.7%6.2%10.5%13.9%13.1%11.0%19.6%14.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is NU Skin Enterprises stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 29% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does NU Skin Enterprises pay a dividend?

Yes. The dividend yield is about 5.92%, and it has paid dividends for 10 years in our data.

Is NU Skin Enterprises a good stock to buy?

We do not give buy or sell advice. NU Skin Enterprises scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.